The Prescribing Clinical Network recommends Tiotropium (Spiriva Respimat®) as a treatment option for adult patients with asthma as an add-on maintenance bronchodilator treatment in patients who are currently treated with:
- Maintenance combination of inhaled corticosteroids (≥ 800micrograms budesonide daily or equivalent) AND
- Long acting beta2-agonists (LABA) AND
- Have experienced one or more severe exacerbations in the previous year AND
- If suitable have had a trial of MART (maintenance & reliever therapy).
Successful treatment would be no further exacerbations in the previous 12 months.
Stop treatment if success criteria not met OR if an increase in steroids is required.
Tiotropium (Spiriva Respimat®) will be considered GREEN on the traffic light system for this indication.
